This two-day conference will serve as a platform to discuss compliance and transparency areas of key concern. Goal is to unravel compliance challenges, define and learn fair market value and develop a consistent, simple and transparent method and strategy for your company.
Quality Assurance Practices in Pharmaceutical Manufacturing to Be Discussed in Moscow
Russian and foreign pharmaceutical companies are gathering in Moscow for the 2nd annual “Quality Assurance in Pharma Manufacturing, Russia and EAEU” conference, organized by Fleming.
The conference's program presents the key aspects of quality assurance: innovative approaches and trends in quality for safety and efficiency assurance; localization; validation and risk management; optimization at the manufacturing site; and creating an effective personnel training system.
The issues being touched upon in the course of the conference are significant for pharmaceutical companies in Russia and in other EAEU countries: Kazakhstan, Armenia, Kyrgyzstan and Belarus. On top of that, guest speakers from European countries will take part in the conference to share their ideas in quality assurance.
Participants will have a chance to meet with Akrikhin, Sanofi, Teva, Bayer, Berlin-Pharma and Petrovax-Pharm representatives, as well as with experts from leading associations to obtain up-to-date information for creating efficient production processes and enhancing the quality of medicines.
The format of working sessions ensures efficient knowledge transfer for all participants, owing to panel discussions, interactive presentations, case studies and “world café” debates taking place during the conference.
The “Quality Assurance in Pharma Manufacturing, Russia and EAEU” conference is officially supported by the Association of International Pharmaceutical Manufacturers (AIPM), the Association of Russian Pharmaceutical Manufacturers (ARPM), the Union of Professional Pharmaceutical Associations (UPPA) and the Pharmaceutical Innovations Association.
Find out more about the event at:
Interested in this topic?
Project & Portfolio Management for Pharma and Biotech – EAST
For the upcoming Project and Portfolio Management for Pharma and Biotech Conference, Fleming presents a high-level meeting building on more than a decade of experience in running global Pharma PPM events worldwide.
Patient Adherence and Engagement
Discuss the issues of non-adherence with other stakeholders and find a solution together with the patients themselves.
Ready for the new GCP ICH E6 (R2) addendum?
On the 23rd of July 2015, the EMA's Committee for Human Medicinal Products released the Guideline for Good Clinical Practice E6(R2) for consultation. On the 14th of June 2017, it will come into effect and influence everyone involved in the clinical research process. What does it mean to pharma and biotech companies, sponsors, CROs, research institutes and third-party organizations?
With improved patient engagement to increased patient adherence
Chronic illnesses are commonly treated with the long-term use of medications. This treatment could be successful, however, its benefits are overshadowed by the fact that 50% of patients don't take their medications as prescribed. Reveal all the alarming numbers of non-adherence and learn how to decrease it with improved patient engagement.
The expanding role of pharmacovigilance and risk management
A profound and accelerated transformation of the Pharmacovigilance world is happening, due to several key drivers. The absolute necessity to ensure that patients can benefit from an early access to new drugs, while ensuring an optimal identification and management of risks is vital.